Optimal initial dose of oral cyclosporine in relation to its toxicities for graft-versus-host disease prophylaxis following reduced-intensity stem cell transplantation in Japanese patients.

Kishi, Y; Murashige, N; Kami, M; Miyakoshi, S; Shibagaki, Y; Hamaki, T; Takaue, Y; Taniguchi, S

Kishi, Y; Murashige, N; Kami, M; Miyakoshi, S; Shibagaki, Y; Hamaki, T; Takaue, Y; Taniguchi, S.

Affiliation

Kishi Y; Haematopoietic Stem Cell Transplantation Unit, the National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Bone Marrow Transplant ; 35(11): 1079-82, 2005 Jun.

Article in En | MEDLINE | ID: mdl-15806118

Subject(s)

Cyclosporine/administration & dosage; Cyclosporine/therapeutic use; Graft vs Host Disease/prevention & control; Immunosuppressive Agents/administration & dosage; Immunosuppressive Agents/therapeutic use; Stem Cell Transplantation/methods; Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Humans; Japan; Middle Aged; Retrospective Studies; Time Factors; Transplantation Conditioning/methods; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Cyclosporine / Stem Cell Transplantation / Graft vs Host Disease / Immunosuppressive Agents Type of study: Observational_studies Limits: Adult / Aged / Humans / Middle aged Country/Region as subject: Asia Language: En Journal: Bone Marrow Transplant Journal subject: TRANSPLANTE Year: 2005 Type: Article Affiliation country: Japan

Search on Google

XML

PubMed Links